An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
Public ClinicalTrials.gov record NCT02531126. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
Study identification
- NCT ID
- NCT02531126
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Celgene
- Industry
- Enrollment
- 877 participants
Conditions and interventions
Conditions
Interventions
- RPC1063 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 1, 2015
- Primary completion
- Dec 18, 2024
- Completion
- Dec 18, 2024
- Last update posted
- Dec 30, 2025
2015 – 2024
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 144 | Tucson | Arizona | 85712 | — |
| Local Institution - 102 | Anaheim | California | 92801 | — |
| Local Institution - 117 | Mission Hills | California | 91345 | — |
| Local Institution - 112 | Oak Lawn | Illinois | 60453 | — |
| Local Institution - 119 | Baton Rouge | Louisiana | 70809 | — |
| Local Institution - 127 | Jacksonville | North Carolina | 28546 | — |
| Local Institution - 290 | Oklahoma City | Oklahoma | 73112 | — |
| Local Institution - 143 | Portland | Oregon | 97239 | — |
| Local Institution - 179 | Germantown | Tennessee | 38138 | — |
| Local Institution - 122 | Dallas | Texas | 75246 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02531126, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 30, 2025 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02531126 live on ClinicalTrials.gov.